Skin & Hair

Melanotan I

Also known as: Afamelanotide, Scenesse, MT-1, CUV1647

FDA Approved
Share:

Popular For

Skin tanning, photoprotection, sun sensitivity disorders

Key Facts: Melanotan I

Category
Skin & Hair
FDA Status
FDA Approved
Clinical Status
FDA Approved (2019) - Erythropoietic Protoporphyria
Administration
Subcutaneous implant (not injection)
Typical Dose
500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance)
Frequency
Daily during loading (1-2 weeks), then 1-2x weekly maintenance
Evidence Level
FDA Approved
Duration
Long-term / as needed before sun season
Also Known As
Afamelanotide, Scenesse, MT-1, CUV1647

Mechanism of Action

Melanotan I binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection. Unlike MT-II, it has minimal affinity for MC3R and MC4R, resulting in fewer sexual and appetite-related side effects.

Research Summary

FDA approved in 2019 for EPP after successful Phase III trials showing significant increase in pain-free time in sunlight. Also studied for vitiligo, polymorphous light eruption, and solar urticaria. Clinuvel Pharmaceuticals developed and markets it as Scenesse.

Clinical Status:FDA Approved (2019) - Erythropoietic Protoporphyria
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance)

Range

250-1000 mcg per injection

Frequency

Daily during loading (1-2 weeks), then 1-2x weekly maintenance

Injected subcutaneously like MT-II. More selective than MT-II with fewer sexual side effects. Slower onset of tanning than MT-II. FDA version (Scenesse) is an implant for EPP patients only.

Research Dosing

Scientific studies

FDA-approved dosing for EPP

Doses from Studies

Duration

Long-term / as needed before sun season

Administration

Subcutaneous implant (not injection)

Timing & Administration

Best Time to Take

Evening or before sun exposure

Daily during loading, then maintenance doses

Food Recommendation

With or without food

Why This Timing?

Similar to MT-II, evening use minimizes visible flushing. Pre-sun exposure maximizes tanning effect.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Nausea (common)
  • Skin darkening (intended effect)
  • Headache
  • Fatigue
  • Injection site reactions
  • FDA approved with known safety profile

References

Related Peptides

Peptides commonly compared with Melanotan I or used in similar applications.

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors
PRO

Want updates on Melanotan I research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.